BR0308277A - Derivados tiazol e oxazol que modulam a atividade de ppar - Google Patents

Derivados tiazol e oxazol que modulam a atividade de ppar

Info

Publication number
BR0308277A
BR0308277A BR0308277-6A BR0308277A BR0308277A BR 0308277 A BR0308277 A BR 0308277A BR 0308277 A BR0308277 A BR 0308277A BR 0308277 A BR0308277 A BR 0308277A
Authority
BR
Brazil
Prior art keywords
thiazole
ppar activity
compounds
oxazole derivatives
modulate ppar
Prior art date
Application number
BR0308277-6A
Other languages
English (en)
Inventor
Xue-Min Cheng
Noe Ouano Erasga
Gary Frederick Filzen
Andrew George Geyer
Chitase Lee
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0308277A publication Critical patent/BR0308277A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26Radicals substituted by sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

"DERIVADOS TIAZOL E OXAZOL QUE MODULAM A ATIVIDADE DE PPAR". Esta invenção descreve compostos que alteram a atividade de PPAR. A invenção também descreve sais farmaceuticamente aceitáveis dos compostos, composições farmaceuticamente aceitáveis que compreendem os compostos ou os seus sais, e métodos para os utilizar como agentes terapêuticos para tratamento ou prevenção de hiperlipidemia e hipercolesteremia em um mamífero. A presente invenção também descreve métodos para fabricar os compostos descritos.
BR0308277-6A 2002-03-07 2003-02-24 Derivados tiazol e oxazol que modulam a atividade de ppar BR0308277A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07
PCT/IB2003/000708 WO2003074050A1 (en) 2002-03-07 2003-02-24 Thiazole and oxazole derivatives which modulate ppar activity

Publications (1)

Publication Number Publication Date
BR0308277A true BR0308277A (pt) 2004-12-28

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308277-6A BR0308277A (pt) 2002-03-07 2003-02-24 Derivados tiazol e oxazol que modulam a atividade de ppar

Country Status (29)

Country Link
US (1) US20030207924A1 (pt)
EP (1) EP1482935B1 (pt)
JP (1) JP2005528348A (pt)
KR (1) KR20040091693A (pt)
AP (1) AP2004003124A0 (pt)
AR (1) AR038881A1 (pt)
AT (1) ATE405260T1 (pt)
AU (1) AU2003206059A1 (pt)
BR (1) BR0308277A (pt)
CA (1) CA2478520A1 (pt)
CO (1) CO5601012A2 (pt)
DE (1) DE60323060D1 (pt)
EA (1) EA200400943A1 (pt)
EC (1) ECSP045285A (pt)
ES (1) ES2310650T3 (pt)
HN (1) HN2003000090A (pt)
IS (1) IS7377A (pt)
MA (1) MA27181A1 (pt)
MX (1) MXPA04007564A (pt)
NO (1) NO20044242L (pt)
OA (1) OA12780A (pt)
PA (1) PA8567801A1 (pt)
PE (1) PE20030989A1 (pt)
PL (1) PL372969A1 (pt)
TN (1) TNSN04168A1 (pt)
TW (1) TW200305403A (pt)
UY (1) UY27695A1 (pt)
WO (1) WO2003074050A1 (pt)
ZA (1) ZA200406068B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CA2524054C (en) * 2003-05-19 2012-04-24 Irm Llc Immunosuppressant compounds and compositions
KR20070004769A (ko) 2004-02-27 2007-01-09 암젠 인코포레이션 대사 장애의 치료에 사용되는 화합물, 약제학적 조성물 및그 사용방법
JP2007536343A (ja) 2004-05-05 2007-12-13 ノボ ノルディスク アクティーゼルスカブ Pparアゴニストとしてのフェノキシ酢酸誘導体
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1751120A4 (en) * 2004-05-25 2010-05-05 Metabolex Inc SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND MANUFACTURING METHOD THEREFOR
EP1749000A4 (en) * 2004-05-25 2009-12-30 Metabolex Inc BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
CN101193876B (zh) * 2005-05-07 2011-05-11 财团法人首尔大学校产学协力财团 制备PPARδ的配体的方法和用于制备该配体的中间化合物
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
EP1916234B1 (en) * 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
CA2621949A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2631390C (en) 2005-12-22 2014-03-11 Per Sauerberg Phenoxy acetic acids as ppar delta activators
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
CA2683751C (en) 2007-04-16 2013-01-08 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
CA2702047C (en) 2007-10-10 2012-04-17 Amgen Inc. Substituted biphenyl gpr40 modulators
WO2009078981A2 (en) * 2007-12-13 2009-06-25 Sri International Ppar-delta ligands and methods of their use
RU2527177C2 (ru) 2007-12-20 2014-08-27 Энвиво Фармасьютикалз, Инк. Четырехзамещенные бензолы
US8450522B2 (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
CA2739888C (en) 2008-10-15 2013-11-19 Amgen Inc. Spirocyclic gpr40 modulators
WO2011105643A1 (ko) * 2010-02-25 2011-09-01 서울대학교산학협력단 퍼록시솜 증식자 활성화 수용체 리간드 셀레나졸 유도체, 이의 제조방법 및 이들 화합물의 용도
EP3043789B1 (en) 2013-09-09 2020-07-08 vTv Therapeutics LLC Use of a ppar-delta agonists for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
CN1233241A (zh) * 1996-08-19 1999-10-27 日本烟草产业株式会社 丙酸衍生物及其用途
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
JP2004517100A (ja) * 2000-12-20 2004-06-10 グラクソ グループ リミテッド hPPARアルファアゴニストとしての置換オキサゾールおよびチアゾール
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
ES2275887T3 (es) * 2001-06-07 2007-06-16 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisoma (ppar).

Also Published As

Publication number Publication date
HN2003000090A (es) 2004-05-05
ES2310650T3 (es) 2009-01-16
EP1482935A1 (en) 2004-12-08
DE60323060D1 (de) 2008-10-02
PA8567801A1 (es) 2003-11-12
ATE405260T1 (de) 2008-09-15
OA12780A (en) 2006-07-07
EA200400943A1 (ru) 2005-02-24
UY27695A1 (es) 2003-10-31
IS7377A (is) 2004-07-29
CA2478520A1 (en) 2003-09-12
JP2005528348A (ja) 2005-09-22
MXPA04007564A (es) 2004-11-10
ECSP045285A (es) 2004-10-26
AR038881A1 (es) 2005-02-02
AP2004003124A0 (en) 2004-09-30
US20030207924A1 (en) 2003-11-06
PE20030989A1 (es) 2003-11-29
NO20044242L (no) 2004-10-06
ZA200406068B (en) 2005-09-06
EP1482935B1 (en) 2008-08-20
WO2003074050A1 (en) 2003-09-12
PL372969A1 (en) 2005-08-08
CO5601012A2 (es) 2006-01-31
TNSN04168A1 (fr) 2007-03-12
KR20040091693A (ko) 2004-10-28
AU2003206059A1 (en) 2003-09-16
MA27181A1 (fr) 2005-01-03
TW200305403A (en) 2003-11-01

Similar Documents

Publication Publication Date Title
BR0308277A (pt) Derivados tiazol e oxazol que modulam a atividade de ppar
BR0308221A (pt) Derivados de tiazol e oxazol que modulam a atividade de ppar
BR0308202A (pt) Tiazóis e oxazóis substituìdos que modulam a atividade de ppar
BR0309169A (pt) Compostos que modulam a atividade ppar e métodos para a sua preparação
BRPI0409486A (pt) compostos que modulam atividade de ppar e métodos para a sua preparação
DK2316831T3 (da) 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
BRPI0615097A2 (pt) agentes para previnir e tratar distúrbios que envolvem modulação dos receptores de ryr
BRPI0510095A (pt) tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina
EA200601746A1 (ru) Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс"
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BR0311591A (pt) 1-(aminoalquil)-2-sulfonilazindóis como ligandos de 5-hidroxitriptamina-6
BRPI0507086A (pt) método para tratar sintomas de depressão, método monoterapêutico para tratar um paciente quanto aos sintomas de depressão, e, uso de um composto de quetiapina ou um seu sal farmaceuticamente aceitável
BR0015436A (pt) Sais de hidroxieicosatetraenoato, composições e métodos de uso no tratamento de distúrbios dos olhos secos
DK1197223T3 (da) Farmaceutisk præparat til forebyggelse, behandling eller udviklingsinhibition af simpel retinopati eller præproliferativ retinopati
PT1131073E (pt) Uso de derivados de estaurosporina para o tratamento de doencas oculares neovasculares
BR0211358A (pt) Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
BR0115615A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto ou de um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento e/ou para a prevenção de doenças infecciosas
BR0316483A (pt) Derivados de n-(4-(piperazin-1-il)-fenil-2-oxazolidinona-5-carboxami da e compostos relacionados como agentes antibacterianos
BR112023021015A2 (pt) Métodos de tratamento de linfoma não hodgkin usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino) isoindolina-1,3-diona
BR112023021959A2 (pt) Compostos para o uso no tratamento de distúrbios hiperproliferativos
BR0206854A (pt) Uso de 2-amino-1-(4-hidróxi-2-metanossulfonamidofenil)eta nol para o tratamento de incontinência urinária
DOP2003000602A (es) Compuestos que modulan la actividad de ppar
BR112023019943A2 (pt) Métodos de tratamento de linfoma de células b usando terapia combinada
AR021749A1 (es) Uso de derivados de tiazolidinediona para el tratamiento o prevencion de cataratas.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 31/426, A61K 31/427, C07D 277/26, C07D 277/24, C07D 417/12, A61P 3/06

Ipc: A61K 31/426 (2011.01), A61K 31/427 (2011.01), C07D

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES.